Herges S, Taylor D A
Department of Pharmaceutical Biology and Pharmacology, Victorian College of Pharmacy, Monash University, Parkville, Australia.
Pharmacol Biochem Behav. 1998 Mar;59(3):595-611. doi: 10.1016/s0091-3057(97)00473-5.
The influence of serotonin (5-HT) antagonists and a selective serotonin reuptake inhibitor (SSRI) on cocaine-induced locomotor activity, rears, and head bobs was investigated in female Glaxo Wistar rats. The SSRI, fluoxetine (10 mg/kg), and the nonselective 5-HT agent, methysergide, at the dose range of 5 and 15 mg/kg enhanced the behaviors produced by cocaine (15 mg/kg) to a similar extent. Moreover, the potentiation of cocaine-induced locomotor activity, rears, and head bobs was even greater after the combined administration of methysergide ( 15 mg/kg) and fluoxetine (10 mg/kg). In order to investigate a possible involvement of 5-HT1A receptors in the observed potentiation by methysergide and fluoxetine, the potent and selective 5-HT1A antagonist, WAY 100635, was used. WAY 100635 (0.1 and 1.5 mg/kg) markedly reduced the behaviors induced by cocaine preceded by fluoxetine (10 mg/kg) and methysergide (5 and 15 mg/kg) pretreatment, respectively, suggesting an involvement of 5-HT1A receptors in the action of fluoxetine and methysergide on cocaine-induced behaviors. An attenuation of the fluoxetine-enhanced cocaine-induced behaviors was also observed after pretreatment with the 5-HT2A antagonist ketanserin (0.1 and 1.0 mg/kg). Coadministration of ketanserin (1.0 mg/kg) and WAY 100635 (1.5 mg/kg) resulted in the greatest blockade of the fluoxetine-enhanced cocaine-induced behaviors. The antagonists and the SSRI, fluoxetine, did not alter the behaviors in comparison to that of saline-treated animals. These results provide evidence for an involvement of 5-HT1A receptors in the enhancing effect of fluoxetine and methysergide on cocaine-induced locomotor activity, rears, and head bobs, and suggest a stimulatory action of methysergide at the 5-HT1A receptor. In addition, some of the actions may also be mediated by activation of the 5-HT2A receptor and/or inhibition of the 5-HT2C receptor.
在雌性葛兰素威斯塔大鼠中,研究了血清素(5-羟色胺,5-HT)拮抗剂和选择性血清素再摄取抑制剂(SSRI)对可卡因诱导的运动活性、竖毛行为和点头行为的影响。SSRI氟西汀(10毫克/千克)以及非选择性5-HT药物麦角酸二乙胺,在5至15毫克/千克的剂量范围内,对可卡因(15毫克/千克)产生的行为增强作用程度相似。此外,联合给予麦角酸二乙胺(15毫克/千克)和氟西汀(10毫克/千克)后,可卡因诱导的运动活性、竖毛行为和点头行为的增强作用甚至更大。为了研究5-HT1A受体是否可能参与麦角酸二乙胺和氟西汀所观察到的增强作用,使用了强效且选择性的5-HT1A拮抗剂WAY 100635。WAY 100635(0.1和1.5毫克/千克)分别显著降低了在氟西汀(10毫克/千克)和麦角酸二乙胺(5和15毫克/千克)预处理后由可卡因诱导的行为,表明5-HT1A受体参与了氟西汀和麦角酸二乙胺对可卡因诱导行为的作用。在用5-HT2A拮抗剂酮色林(0.1和1.0毫克/千克)预处理后,也观察到氟西汀增强的可卡因诱导行为有所减弱。联合给予酮色林(1.0毫克/千克)和WAY 100635(1.5毫克/千克)导致对氟西汀增强的可卡因诱导行为的最大阻断。与生理盐水处理的动物相比,拮抗剂和SSRI氟西汀未改变行为。这些结果为5-HT1A受体参与氟西汀和麦角酸二乙胺对可卡因诱导的运动活性、竖毛行为和点头行为的增强作用提供了证据,并表明麦角酸二乙胺在5-HT1A受体处具有刺激作用。此外,某些作用也可能由5-HT2A受体激活和/或5-HT2C受体抑制介导。